Key Insights on Gross Profit: Catalent, Inc. vs Ligand Pharmaceuticals Incorporated

Catalent vs Ligand: A Decade of Gross Profit Trends

__timestampCatalent, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 201459860000055402000
Thursday, January 1, 201561530000066107000
Friday, January 1, 2016587600000103402000
Sunday, January 1, 2017654600000135736000
Monday, January 1, 2018752600000245116000
Tuesday, January 1, 2019805100000108935000
Wednesday, January 1, 2020983300000156000000
Friday, January 1, 20211352000000214957000
Saturday, January 1, 20221640000000143418000
Sunday, January 1, 2023106000000096265000
Monday, January 1, 2024953000000
Loading chart...

Unlocking the unknown

A Comparative Analysis of Gross Profit Trends: Catalent, Inc. vs Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. Catalent, Inc. and Ligand Pharmaceuticals Incorporated, two prominent players, have shown distinct trajectories in their gross profit over the past decade. From 2014 to 2023, Catalent's gross profit surged by approximately 77%, peaking in 2022. This growth reflects Catalent's strategic expansions and innovations. In contrast, Ligand Pharmaceuticals experienced a more modest increase of around 160% from 2014 to 2021, with a notable peak in 2018. However, data for 2024 is missing, indicating potential reporting delays or strategic shifts. This analysis highlights the dynamic nature of the pharmaceutical sector, where companies must continuously adapt to maintain profitability. Investors and industry analysts should consider these trends when evaluating future growth prospects.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025